Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Aug 19:11:1235-42.
doi: 10.2147/TCRM.S65650. eCollection 2015.

Patient considerations in the management of ulcerative colitis - role of vedolizumab

Megha Kothari  1 , Prashant Mudireddy  1 , Arun Swaminath  1
Affiliations
Review

Patient considerations in the management of ulcerative colitis - role of vedolizumab

Megha Kothari et al. Ther Clin Risk Manag. .

Abstract

Ulcerative colitis (UC) is a subtype of inflammatory bowel disease which causes inflammation of the large intestine and affects approximately 7.6-24.6 per 100,000 persons. The therapeutic goal for UC patients is inducing remission, maintaining remission, and ideally, obtaining mucosal healing. Vedolizumab, approved by the US Food and Drug Administration in May 2014 for the treatment of moderate-to-severe UC and Crohn's disease, is a newly developed anti-integrin therapy. This review focuses on the preclinical development of vedolizumab and data from early trials, and details the results of the landmark trails that led to its approval in the USA with a specific focus on the management of UC. Additionally, data on safety and the current UC management protocols are also discussed.

Keywords: immunomodulator drugs; inflammation; infliximab; mucosal healing; remission; ulcerative colitis.

PubMed Disclaimer

References

    1. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365(18):1713–1725. - PubMed
    1. Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147(3):618e3–627e3. - PubMed
    1. Gilroy L, Allen PB. Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn’s disease? Clin Exp Gastroenterol. 2014;7:163–172. - PMC - PubMed
    1. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146(12):829–838. - PubMed
    1. Deleporte A, Viennot S, Dupont B, et al. Efficacy of anti-TNF-alpha monoclonal antibodies in inflammatory bowel disease treatment. Int J Infereron Cytokine Mediator Res. 2013;2013(5):11–31.